UC Davis Cancer Center researchers have developed a novel peptide that binds to the surface of leukemia and lymphoma cells with extremely high affinity, specificity and stability, and demonstrates remarkable promise as a tool to help image tumors and deliver anti-cancer drugs. The research was reported in Nature Chemical Biology. Kit Lam, professor and chief of hematology and oncology at UC Davis Cancer Center and senior author of the paper, says this peptide has great potential for becoming a new, effective imaging and therapeutic agent for patients with lymphoid cancers.